Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma

María‐Victoria Mateos; Katja Weisel; Evangelos Terpos; Sossana Delimpasi; Efstathios Kastritis; Elena Zamagni; Michel Delforge; Enrique M. Ocio; Eirini Katodritou; Francesca Gay; Alessandra Larocca; Xavier Leleu; Paula Rodríguez‐Otero; Fredik Schjesvold; Michèle Cavo; Meletios A Dimopoulos

doi:10.3324/haematol.2023.284694

Article2023

PB2127: REAL-WORLD EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN TRIPLE CLASS REFRACTORY PATIENTS WITH MULTIPLE MYELOMA

Ioannis Ntanasis‐Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Μαρία Ρούσσου, Evangelos Eleutherakis‐Papaiakovou, Foteini Theodorakakou, Vassiliki Spiliopoulou, Efstathios Kastritis, Evangelos Terpos, Meletios A Dimopoulos, Maria Gavriatopoulou

Article2023

P-301 Real-world outcomes of belantamab mafodotin monotherapy in triple class refractory patients with multiple myeloma

Ioannis Ntanasis‐Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Μαρία Ρούσσου, Evangelos Eleutherakis‐Papaiakovou, Foteini Theodorakakou, Vassiliki Spiliopoulou, Efstathios Kastritis, Evangelos Terpos, Meletios A Dimopoulos, Maria Gavriatopoulou

Article2023

Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma

Ioannis Ntanasis‐Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Μαρία Ρούσσου, Evangelos Eleutherakis‐Papaiakovou, Vassiliki Spiliopoulou, Efstathios Kastritis, Evangelos Terpos, Meletios A Dimopoulos, Maria Gavriatopoulou

Article2025

The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development

Pralay Mukhopadhyay, Hesham Abdullah, Joanna Opalinska, Prani Paka, Eric Richards, Katja Weisel, Suzanne Trudel, María‐Victoria Mateos, Meletios A Dimopoulos, Sagar Lonial

Article2023

Impact of Long-Term Treatment with Belantamab Mafodotin on Safety and Efficacy Outcomes in Patients with Relapsed/Refractory Multiple Myeloma in DREAMM-3

Vânia T. M. Hungria, Katja Weisel, Atanas Radinoff, Sosana Delimpasi, Gábor Mikala, Tamás Masszi, Li J, Marcelo Capra, Ângelo Maiolino, Vasiliki Pappa, Dominik Chraniuk, Iurii Osipov, Xavier Leleu, Michael Löw, Morio Matsumoto, Mary Li, Neal Sule, Margaret Polinkovsky, Randy Davis, Shelley Bright, Astrid McKeown, Joanna Opalińska, Meletios A Dimopoulos

Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma

Abstract

Discussion(0)

Related publications

PB2127: REAL-WORLD EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN TRIPLE CLASS REFRACTORY PATIENTS WITH MULTIPLE MYELOMA

P-301 Real-world outcomes of belantamab mafodotin monotherapy in triple class refractory patients with multiple myeloma

Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma

The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development

Impact of Long-Term Treatment with Belantamab Mafodotin on Safety and Efficacy Outcomes in Patients with Relapsed/Refractory Multiple Myeloma in DREAMM-3